Biotechnology Notching up another indication for its mega-blockbuster anti-PD-1 therapy, the US Food and Drug Administration has now approved Merck & Co’s Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1), as determined by an FDA-approved test. 13 October 2021